Citadel Advisors’s CureVac CVAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-19,600
| Closed | -$106K | – | 12849 |
|
|
2025
Q3 | $106K | Sell |
19,600
-67,800
| -78% | -$367K | ﹤0.01% | 11819 |
|
|
2025
Q2 | $475K | Buy |
87,400
+42,000
| +93% | +$167K | ﹤0.01% | 8756 |
|
|
2025
Q1 | $126K | Buy |
45,400
+43,100
| +1,874% | +$150K | ﹤0.01% | 11144 |
|
|
2024
Q4 | $7.84K | Sell |
2,300
-22,200
| -91% | -$64K | ﹤0.01% | 13711 |
|
|
2024
Q3 | $72K | Sell |
24,500
-15,100
| -38% | -$49.7K | ﹤0.01% | 11520 |
|
|
2024
Q2 | $135K | Buy |
39,600
+3,100
| +8% | +$10.1K | ﹤0.01% | 10499 |
|
|
2024
Q1 | $111K | Buy |
36,500
+8,500
| +30% | +$29.8K | ﹤0.01% | 11213 |
|
|
2023
Q4 | $118K | Buy |
28,000
+14,200
| +103% | +$77K | ﹤0.01% | 10727 |
|
|
2023
Q3 | $94.3K | Hold |
13,800
| – | – | ﹤0.01% | 10973 |
|
|
2023
Q2 | $144K | Buy |
13,800
+3,700
| +37% | +$33.1K | ﹤0.01% | 10403 |
|
|
2023
Q1 | $70.4K | Sell |
10,100
-47,900
| -83% | -$418K | ﹤0.01% | 11723 |
|
|
2022
Q4 | $350K | Buy |
58,000
+11,100
| +24% | +$82K | ﹤0.01% | 8978 |
|
|
2022
Q3 | $370K | Buy |
46,900
+3,100
| +7% | +$36.1K | ﹤0.01% | 9112 |
|
|
2022
Q2 | $596K | Sell |
43,800
-52,500
| -55% | -$868K | ﹤0.01% | 8239 |
|
|
2022
Q1 | $1.89M | Sell |
96,300
-45,300
| -32% | -$905K | ﹤0.01% | 6214 |
|
|
2021
Q4 | $4.86M | Sell |
141,600
-49,700
| -26% | -$2M | ﹤0.01% | 4339 |
|
|
2021
Q3 | $10.4M | Sell |
191,300
-4,600
| -2% | -$277K | ﹤0.01% | 3002 |
|
|
2021
Q2 | $14.4M | Buy |
195,900
+63,000
| +47% | +$6.3M | ﹤0.01% | 2530 |
|
|
2021
Q1 | $12.2M | Sell |
132,900
-29,300
| -18% | -$2.84M | ﹤0.01% | 2690 |
|
|
2020
Q4 | $13.2M | Buy |
162,200
+51,900
| +47% | +$3.97M | ﹤0.01% | 2287 |
|
|
2020
Q3 | $5.13M | Buy |
+110,300
| New | +$6.15M | ﹤0.01% | 3119 |
|
Citadel Advisors's CVAC Position: Q1 2026 in Review
Citadel Advisors sold out of CureVac (CVAC) in Q1 2026, closing a stake of 261,097 shares — an estimated $1.18M sold.
Citadel Advisors first reported a position in CVAC in Q4 2020 and held it in 18 quarters. The position peaked at $24.5M in Q2 2023. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.
- Citadel Advisors reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 261,097 CureVac shares in Q1 2026, an estimated $1.18M.
- Citadel Advisors first reported a position in CureVac in Q4 2020 and held it in 18 quarters.
- Citadel Advisors's CureVac position peaked at $24.5M in Q2 2023.
- 0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.